Investigating a metabolic pathway in kidney disease for targeted therapies
GSTM1-Transsulfuration metabolic axis in kidney disease: therapeutic target in precision medicine
['FUNDING_R01'] · UNIVERSITY OF ROCHESTER · NIH-11060042
This study is looking at how a missing enzyme called GSTM1 might make kidney disease worse, and it aims to find new treatment options for people with chronic kidney disease by exploring how this enzyme affects important processes in the body.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11060042 on ClinicalTrials.gov |
What this research studies
This research focuses on the role of the GSTM1 enzyme in kidney disease, particularly how its deficiency may lead to faster progression of chronic kidney disease (CKD). The study examines the metabolic pathways influenced by GSTM1, including the balance of hydrogen sulfide, which is crucial for cell metabolism and signaling. By understanding these mechanisms, the research aims to identify potential therapeutic targets for precision medicine in patients with kidney disease, especially among those with specific genetic backgrounds. The approach includes both animal models and human population studies to validate findings.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals, particularly African Americans, who are genetically predisposed to GSTM1 deficiency and are experiencing chronic kidney disease.
Not a fit: Patients without GSTM1 deficiency or those with kidney disease unrelated to this metabolic pathway may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, targeted treatments for kidney disease that improve patient outcomes and slow disease progression.
How similar studies have performed: Previous studies have shown associations between GSTM1 deficiency and increased risks of kidney disease, suggesting that this research builds on established findings rather than exploring entirely novel territory.
Where this research is happening
ROCHESTER, UNITED STATES
- UNIVERSITY OF ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LE, THU H. — UNIVERSITY OF ROCHESTER
- Study coordinator: LE, THU H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.